NASDAQ:TNYA Tenaya Therapeutics (TNYA) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free TNYA Stock Alerts $4.22 -0.16 (-3.65%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$3.97▼$4.3050-Day Range$4.22▼$6.8052-Week Range$1.66▼$8.09Volume384,556 shsAverage Volume551,989 shsMarket Capitalization$331.35 millionP/E RatioN/ADividend YieldN/APrice Target$15.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Tenaya Therapeutics alerts: Email Address Tenaya Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside264.9% Upside$15.40 Price TargetShort InterestBearish5.41% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$10 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.70) to ($1.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.57 out of 5 starsMedical Sector672nd out of 908 stocksBiological Products, Except Diagnostic Industry112th out of 151 stocks 3.5 Analyst's Opinion Consensus RatingTenaya Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTenaya Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.41% of the float of Tenaya Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenaya Therapeutics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Tenaya Therapeutics has recently increased by 9.06%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTenaya Therapeutics does not currently pay a dividend.Dividend GrowthTenaya Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TNYA. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for TNYA on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Tenaya Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tenaya Therapeutics insiders have bought 8,038.88% more of their company's stock than they have sold. Specifically, they have bought $9,999,999.00 in company stock and sold $122,867.00 in company stock.Percentage Held by Insiders33.83% of the stock of Tenaya Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.54% of the stock of Tenaya Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Tenaya Therapeutics are expected to decrease in the coming year, from ($1.70) to ($1.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tenaya Therapeutics is -2.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tenaya Therapeutics is -2.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTenaya Therapeutics has a P/B Ratio of 2.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Tenaya Therapeutics Stock (NASDAQ:TNYA)Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Read More TNYA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TNYA Stock News HeadlinesApril 14, 2024 | finance.yahoo.comInstitutions own 33% of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) shares but private equity firms control 44% of the companyApril 5, 2024 | markets.businessinsider.comTenaya Therapeutics’ Strategic Advantages in Cardiovascular Genetic Medicine Garner Buy RatingApril 26, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 29, 2024 | markets.businessinsider.comOptimistic Buy Rating for Tenaya Therapeutics Based on Promising Gene Therapy Pipeline and Upcoming Clinical MilestonesMarch 26, 2024 | finance.yahoo.com20 Countries with the Highest Heart Disease Deaths Per CapitaMarch 21, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Vera Therapeutics (VERA), Tyra Bioscience (TYRA) and Tenaya Therapeutics (TNYA)March 21, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Sera Prognostics (SERA), Tenaya Therapeutics (TNYA)March 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA) and Sera Prognostics (SERA)April 26, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 20, 2024 | finance.yahoo.comTenaya Therapeutics Inc Reports Full Year and Q4 2023 Financial ResultsMarch 19, 2024 | markets.businessinsider.comBuy Rating Justified by Tenaya Therapeutics’ Strong Financials and Promising Cardiovascular Pipeline ProgressMarch 19, 2024 | finanznachrichten.deTenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 18, 2024 | investorplace.comTNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q4 2023March 18, 2024 | globenewswire.comTenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 18, 2024 | globenewswire.comTenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications MedicineFebruary 27, 2024 | globenewswire.comTenaya Therapeutics to Participate in Upcoming March Investor ConferencesFebruary 26, 2024 | globenewswire.comTenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature CommunicationsFebruary 18, 2024 | 247wallst.comInsider Buying: Taking a Controlling Stake in a Struggling Retailer?February 16, 2024 | finance.yahoo.comTNYA Mar 2024 7.500 putFebruary 16, 2024 | finance.yahoo.comTNYA Apr 2024 7.500 putFebruary 9, 2024 | msn.comTenaya Therapeutics Announces Speculative Offering OutlookFebruary 9, 2024 | finance.yahoo.comWall Street Analysts Think Tenaya Therapeutics, Inc. (TNYA) Could Surge 273.1%: Read This Before Placing a BetFebruary 9, 2024 | msn.comTenaya Therapeutics Secures $50 Million in Share SaleFebruary 8, 2024 | markets.businessinsider.comTenaya Announces Pricing Of $50 Mln Underwritten Offering; Stock UpFebruary 8, 2024 | finance.yahoo.comTenaya Therapeutics Announces Pricing of Underwritten OfferingFebruary 6, 2024 | msn.com5 Russell 2000 Stocks Poised to Give the Large Caps a Run for Their MoneyJanuary 26, 2024 | finance.yahoo.comTenaya Therapeutics, Inc. (TNYA) Upgraded to Strong Buy: Here's WhySee More Headlines Receive TNYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tenaya Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today4/25/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TNYA CUSIPN/A CIK1858848 Webwww.tenayatherapeutics.com Phone650-825-6990FaxN/AEmployees140Year FoundedN/APrice Target and Rating Average Stock Price Target$15.40 High Stock Price Target$20.00 Low Stock Price Target$7.00 Potential Upside/Downside+264.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-124,080,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-69.94% Return on Assets-59.80% Debt Debt-to-Equity RatioN/A Current Ratio4.91 Quick Ratio4.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.05 per share Price / Book2.06Miscellaneous Outstanding Shares78,520,000Free Float51,955,000Market Cap$331.35 million OptionableOptionable Beta2.60 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Faraz Ali M.B.A. (Age 51)CEO, Secretary & Director Comp: $816.39kDr. Deepak Srivastava M.D. (Age 58)Scientific Founder, Chairman of Scientific Advisory Board & Director Comp: $118kDr. Timothy Hoey Ph.D. (Age 65)Chief Scientific Officer Comp: $573kDr. Whittemore G. Tingley M.D. (Age 56)PH.D., Chief Medical Officer Comp: $621.98kDr. Eric N. Olson Ph.D.Scientific Founder & Member of Scientific Advisory BoardDr. Bruce R. ConklinScientific FounderDr. Saptarsi Haldar M.D.Scientific FounderDr. Sheng Ding Ph.D.Scientific FounderDr. Benoit G. Bruneau Ph.D.Scientific FounderMs. Leone D. Patterson M.B.A. (Age 62)Chief Financial & Business Officer Comp: $448.55kMore ExecutivesKey CompetitorsPrecigenNASDAQ:PGENTScan TherapeuticsNASDAQ:TCRXSolid BiosciencesNASDAQ:SLDBAura BiosciencesNASDAQ:AURACaribou BiosciencesNASDAQ:CRBUView All CompetitorsInsiders & InstitutionsAtticus Wealth Management LLCSold 12,812 shares on 4/17/2024Ownership: 0.072%HighPoint Advisor Group LLCBought 70,390 shares on 3/26/2024Ownership: 0.090%Timothy HoeySold 3,300 sharesTotal: $23,100.00 ($7.00/share)Timothy HoeySold 6,569 sharesTotal: $35,078.46 ($5.34/share)Timothy HoeySold 4,681 sharesTotal: $27,430.66 ($5.86/share)View All Insider TransactionsView All Institutional Transactions TNYA Stock Analysis - Frequently Asked Questions Should I buy or sell Tenaya Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tenaya Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TNYA shares. View TNYA analyst ratings or view top-rated stocks. What is Tenaya Therapeutics' stock price target for 2024? 7 equities research analysts have issued 12-month price targets for Tenaya Therapeutics' shares. Their TNYA share price targets range from $7.00 to $20.00. On average, they anticipate the company's stock price to reach $15.40 in the next year. This suggests a possible upside of 264.9% from the stock's current price. View analysts price targets for TNYA or view top-rated stocks among Wall Street analysts. How have TNYA shares performed in 2024? Tenaya Therapeutics' stock was trading at $3.24 at the start of the year. Since then, TNYA stock has increased by 30.2% and is now trading at $4.22. View the best growth stocks for 2024 here. Are investors shorting Tenaya Therapeutics? Tenaya Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,090,000 shares, an increase of 21.2% from the March 15th total of 2,550,000 shares. Based on an average daily trading volume, of 609,900 shares, the days-to-cover ratio is presently 5.1 days. Currently, 5.0% of the company's stock are short sold. View Tenaya Therapeutics' Short Interest. When is Tenaya Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our TNYA earnings forecast. How were Tenaya Therapeutics' earnings last quarter? Tenaya Therapeutics, Inc. (NASDAQ:TNYA) announced its quarterly earnings results on Monday, March, 18th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.05. What ETFs hold Tenaya Therapeutics' stock? ETFs with the largest weight of Tenaya Therapeutics (NASDAQ:TNYA) stock in their portfolio include Tema Cardiovascular and Metabolics ETF (HRTS). When did Tenaya Therapeutics IPO? Tenaya Therapeutics (TNYA) raised $150 million in an initial public offering on Friday, July 30th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. Who are Tenaya Therapeutics' major shareholders? Tenaya Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Atticus Wealth Management LLC (0.07%). Insiders that own company stock include David V Goeddel, Deepak Srivastava, Eli Casdin, Faraz Ali, Group Gp Lp Column III and Timothy Hoey. View institutional ownership trends. How do I buy shares of Tenaya Therapeutics? Shares of TNYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TNYA) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsThe World's First "$20 Trillion Drug?"Behind the MarketsI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
